# EDGAR Filing Document

**Accession Number:** 0001595353
**File Stem:** 0001641172-25-024005
**Filing Date:** 2025-8
**Character Count:** 3296
**Document Hash:** 23f3a89b1ec048319e976ca39bf50f94
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-024005.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001641172-25-024005

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250814

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Galmed Pharmaceuticals Ltd.
- **CENTRAL INDEX KEY:** 0001595353
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981147233
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36345
- **FILM NUMBER:** 251218767

**BUSINESS ADDRESS:**
- **STREET 1:** C/O MEITAR LAW OFFICES
- **STREET 2:** 16 ABBA HILLEL SILVER RD.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250608
- **BUSINESS PHONE:** 97236938448

**MAIL ADDRESS:**
- **STREET 1:** C/O MEITAR LAW OFFICES
- **STREET 2:** 16 ABBA HILLEL SILVER RD.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250608

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of August 2025

001-36345

(Commission File Number)

**GALMED PHARMACEUTICALS LTD.**

(Exact name of Registrant as specified in its charter)

**c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On August 14, 2025, Galmed Pharmaceuticals Ltd. (the "Company") convened a Special General Meeting of Shareholders (the "Meeting"), however, the Meeting was adjourned for one day to the same time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Friday, August 15, 2025 at 4:00 p.m., Israel time at the at the offices of Meitar \| Law Offices, legal counsel to the Company at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

This Form 6-K is incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. [333-206292](https://www.sec.gov/Archives/edgar/data/1595353/000114420415048005/v417828_s8.htm),<u> </u>[333-227441](https://www.sec.gov/Archives/edgar/data/1595353/000114420418050116/tv503188_s8.htm), and [333-284163](https://www.sec.gov/Archives/edgar/data/1595353/000149315225001231/forms-8.htm)) and the Company's Registration Statement on Form F-3 (Registration Nos. [333-272722](https://www.sec.gov/Archives/edgar/data/1595353/000149315223042520/formposam.htm) and [333-283241](https://www.sec.gov/Archives/edgar/data/1595353/000149315224046041/formf-3.htm)).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Galmed Pharmaceuticals Ltd.** | **Galmed Pharmaceuticals Ltd.** |
| Date: August 14, 2025 | By: | */s/ Allen Baharaff* |
|  |  | Allen Baharaff |
|  |  | President and Chief Executive Officer |

---